@article{trunda2013use,
  title = {The Use of two Mesenchymal Stem Cell Doses as a Treatment for a Horse with Superficial Digital Flexor Tendinopathy},
  author = {Miroslav Trunda and Sarka Vosahlikova and Klara Prajzlerova and Marika Stepankova and Josef Bodor and Radek Klubal},
  year = 2013,
  url = {https://ibimapublishing.com/articles/IJVMR/2013/703351/},
  journal = {International Journal of Veterinary Medicine: Research & Reports},
  volume = 2013 (2013),
  pages = 7,
  doi = 10.5171/2013.703351,
  abstract = {A clinical examination and ultrasonograph of an eight year old gelding revealed tendinopathy of a superficial digital flexor tendon (SDFT) after an injury in a cross-country race. The horse was treated using ex vivo-expanded autologous mesenchymal stem cells (MSCs) derived from bone marrow because of their immunoregulatory properties and their ability to heal cartilage and tendon under specific inflammatory conditions, such as trauma. The first application of MSCs into the lesion was performed on day 37 after the injury, and the second one on day 60. After the treatment with MSCs, the tissue of the injured tendon was nearly completely healed on day 120 after the injury. The horse started to compete in international eventing three months later, once again reaching a similar standard of performance.  },
  keywords = {Mesenchymal stem cells (MSCs), horse, tendonitis, bone marrow},
  note = Article ID: 703351
}